Latest Deals
The acquisition is said to complement Zimmer’s global presence and current infrastructure. Credit: JHVEPhoto / Shutterstock
Zimmer acquires Paragon 28 in $1.2bn deal
Zimmer Biomet has completed the previously announced acquisition of Paragon 28 for an enterprise value of approximately $1.2bn. Announced in January, the acquisition is set to widen and bolster Zimmer Biomet’s offerings in the foot and ankle orthopaedic area. Leveraging Paragon 28’s technology platform, Zimmer Biomet aims to enhance its current portfolios of fracture and trauma, and joint replacement.
Deepull raises $57m in Series C funds for advancing pathogen detection system
Spanish medical diagnostics company deepull has closed an oversubscribed Series C financing round, securing €50m ($56.8m). The funds are earmarked for the final stages of clinical validation and to accelerate the regulatory approval process of its UllCORE diagnostic system for pathogen detection.
SafeHeal nets $40m to advance endoluminal bypass sheath
SafeHeal has pulled in €35m ($39.7m) in Series C equity financing to validate its Colovac endoluminal bypass system. The oversubscribed funding round was led by Solar Eclipse and included participation from new investors, including Gideon Strategic Partners and M&L Healthcare. Existing investor Sofinnova Partners also participated.
Biolinq raises $100m to support US launch of intradermal glucose sensor
Biolinq has secured $100m in a Series C funding round to support the regulatory approval process in the US as it aims to launch its autonomous intradermal glucose sensor to the market. The investment round was spearheaded by Alpha Wave Ventures and saw contributions from several current investors, including Features Capital, Hikma Ventures, and Taisho Pharmaceutical.
